3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Completed
12
Active not recruiting
7
Unknown
3
Recruiting
3
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
2
Castration-resistant Prostate Cancer
1
Interventions
Docetaxel
33
Radiosurgery
23
Radiotherapy
21
Sunitinib
20
pembrolizumab
18
Gemcitabine
16
Cisplatin
16
Androgen Antagonists
15
Nivolumab
14
enzalutamide
13
Goserelin
13
Prednisone
12
Leuprolide
12
Blood Specimen Collection
12
Abiraterone Acetate
12
bicalutamide
11
aldesleukin
11
Surveys and Questionnaires
11
Cyclophosphamide
11
Gonadotropin-Releasing Hormone
10
Bevacizumab
10
Multiparametric Magnetic Resonance Imaging
9
Carboplatin
9
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
8
Triptorelin Pamoate
8
Radiotherapy, Intensity-Modulated
8
Filgrastim
8
Epirubicin
8
Chemotherapy, Adjuvant
8
Brachytherapy
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Unknown
×
Radium-223
×
Genitourinary
×
Clear all
NCT03432949
2024-01-24
TRANCE
University Health Network, Toronto
Phase 4
Unknown
24 enrolled
NCT03305224
2021-09-09
CORE-OCU
Osaka City University
Phase 2
Unknown
10 enrolled
NCT04110782
2019-10-01
RaProRad
Azienda Policlinico Umberto I
Unknown
400 enrolled